IL87628A - Stabilised erythropoietin preparations and process for the production thereof - Google Patents

Stabilised erythropoietin preparations and process for the production thereof

Info

Publication number
IL87628A
IL87628A IL87628A IL8762888A IL87628A IL 87628 A IL87628 A IL 87628A IL 87628 A IL87628 A IL 87628A IL 8762888 A IL8762888 A IL 8762888A IL 87628 A IL87628 A IL 87628A
Authority
IL
Israel
Prior art keywords
stabilised
production
preparations
erythropoietin
erythropoietin preparations
Prior art date
Application number
IL87628A
Other languages
English (en)
Other versions
IL87628A0 (en
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of IL87628A0 publication Critical patent/IL87628A0/xx
Publication of IL87628A publication Critical patent/IL87628A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
IL87628A 1987-09-05 1988-08-31 Stabilised erythropoietin preparations and process for the production thereof IL87628A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19873729863 DE3729863A1 (de) 1987-09-05 1987-09-05 Stabilisierte erythropoietin-lyophilisate

Publications (2)

Publication Number Publication Date
IL87628A0 IL87628A0 (en) 1989-01-31
IL87628A true IL87628A (en) 1993-07-08

Family

ID=6335375

Family Applications (1)

Application Number Title Priority Date Filing Date
IL87628A IL87628A (en) 1987-09-05 1988-08-31 Stabilised erythropoietin preparations and process for the production thereof

Country Status (29)

Country Link
US (1) US4992419A (cs)
EP (1) EP0306824B1 (cs)
JP (1) JPH0780782B2 (cs)
KR (1) KR960009929B1 (cs)
CN (1) CN1027224C (cs)
AT (1) ATE77556T1 (cs)
AU (1) AU610636B2 (cs)
CA (1) CA1330301C (cs)
CS (1) CS274681B2 (cs)
DD (1) DD273004A5 (cs)
DE (2) DE3729863A1 (cs)
DK (1) DK174811B1 (cs)
ES (1) ES2051806T3 (cs)
FI (1) FI93517C (cs)
GR (1) GR3005454T3 (cs)
HK (1) HK89495A (cs)
HU (1) HU202761B (cs)
IE (1) IE60310B1 (cs)
IL (1) IL87628A (cs)
LV (1) LV10178B (cs)
MX (1) MX12880A (cs)
NO (1) NO178687C (cs)
NZ (1) NZ225975A (cs)
PH (1) PH25618A (cs)
PL (1) PL157944B1 (cs)
PT (1) PT88417B (cs)
RU (2) RU2043118C1 (cs)
UA (2) UA26855C2 (cs)
ZA (1) ZA886528B (cs)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
NZ232813A (en) * 1989-03-10 1992-08-26 Snow Brand Milk Products Co Ltd Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons
JPH0341033A (ja) * 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
DE4014654A1 (de) * 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DE4126984A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, gut vertraeglichen arzneimitteln fuer infusions- oder injektionszwecke
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US20030035845A1 (en) * 1992-06-11 2003-02-20 Zale Stephen E. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) * 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5674534A (en) * 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5661125A (en) * 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
EP0582933A1 (de) * 1992-08-11 1994-02-16 F. Hoffmann-La Roche Ag Therapeutisches System zur parenteralen Verabreichung von hämatopoetischen Wachstumsfaktoren
DE4242919A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
FR2719479B1 (fr) * 1994-05-04 1996-07-26 Sanofi Elf Formulation stable lyophilisée comprenant une protéine: kit de dosage.
JP2747979B2 (ja) * 1994-08-19 1998-05-06 雪印乳業株式会社 ヒト由来の糖蛋白質からなる生理活性因子を有効成分とする医薬
IL116085A (en) * 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
AU710347B2 (en) * 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
DE19539574A1 (de) * 1995-10-25 1997-04-30 Boehringer Mannheim Gmbh Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren
US20030138402A1 (en) * 1995-12-25 2003-07-24 Otsuka Pharmaceutical Co., Ltd. Dry compositions
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US20030190307A1 (en) * 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
KR101042660B1 (ko) * 1996-12-24 2011-06-20 바이오겐 아이덱 엠에이 인코포레이티드 안정한 액체 인터페론 제제
DE19716154A1 (de) * 1997-04-18 1998-10-22 Boehringer Mannheim Gmbh Stabile pharmazeutische Darreichungsform für Peptide, Proteine und Nukleinsäuren
RU2152206C1 (ru) * 1997-05-22 2000-07-10 Государственный научный центр вирусологии и биотехнологии "Вектор" Таблетированная форма рекомбинантного человеческого эритропоэтина для перорального применения и способ ее получения
US6391633B1 (en) * 1997-07-23 2002-05-21 Roche Diagnostics Gmbh Production of erythropoietin by endogenous gene activation
US6548296B1 (en) * 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
EP0965349A1 (de) * 1998-06-18 1999-12-22 Roche Diagnostics GmbH Verwendung von Erythropoietin zur Behandlung von Hämochromatosen
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
RU2128517C1 (ru) * 1998-07-20 1999-04-10 Колобков Сергей Леонидович Стабилизированный водный раствор эритропоэтина
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤
CN1165339C (zh) * 1999-04-09 2004-09-08 奥索-麦克尼尔药品公司 红细胞生成素药物组合物
US7345019B1 (en) * 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
DE60038386T2 (de) * 1999-09-08 2009-04-23 Chugai Seiyaku K.K. Stabile proteinlösung abgefüllt in einem behältnis aus hydrophobem harz und eine methode zur stabilisierung derselben
RU2182141C2 (ru) * 2000-03-20 2002-05-10 Братский государственный технический университет Композиция для изготовления легкобетонных изделий
AU2005225151B2 (en) * 2000-05-15 2008-05-29 F. Hoffmann-La Roche Ag New pharmaceutical composition
DE60109625T3 (de) * 2000-05-15 2017-08-03 F. Hoffmann-La Roche Ag Flüssige arzneizubereitung enthaltend ein erythropoietin derivat
AU2001277781A1 (en) * 2000-08-11 2002-02-25 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing preparations
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
RU2191594C1 (ru) * 2001-04-03 2002-10-27 Григорян Седа Суреновна Средство и способ повышения резистентности к инфекции
RU2192882C1 (ru) * 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
DE10149030A1 (de) 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
SI21257A (sl) * 2002-07-17 2004-02-29 LEK farmacevtska dru�ba d.d. Stabilni farmacevtski pripravek, ki vsebuje eritropoietin
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
ATE553747T1 (de) 2003-06-10 2012-05-15 Lg Life Sciences Ltd Stabile wässrige lösung von human-erythropoietin, die kein serumalbumin enthält
FR2857267B1 (fr) * 2003-07-09 2006-03-10 Lab Francais Du Fractionnement Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
JP2007517769A (ja) * 2003-09-29 2007-07-05 ウォーレン ファーマシューティカルズ，インコーポレーテッド 敗血症および癒着形成の治療および予防のための組織保護性サイトカイン
US7141544B2 (en) * 2003-10-10 2006-11-28 Baxter International, Inc. Stabilization of pharmaceutical protein formulations with small peptides
EP1537876A1 (en) * 2003-12-01 2005-06-08 BioGeneriX AG Erythropoietin solution formulation
DE202004020676U1 (de) * 2004-03-10 2005-11-10 Bioceuticals Arzneimittel Ag Erythropoietin-Flüssigformulierung
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
AU2009282446B2 (en) * 2008-08-15 2016-03-31 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
US8748573B2 (en) * 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
HUE034190T2 (en) * 2009-11-03 2018-01-29 Ironwood Pharmaceuticals Inc Linaclitaxel for the treatment of chronic constipation
ES2700925T3 (es) 2010-01-19 2019-02-20 Hanmi Science Co Ltd Formulaciones líquidas para conjugado de eritropoyetina de acción prolongada
WO2011103311A2 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc Treatments for gastrointestinal disorders
PL2603232T3 (pl) 2010-08-11 2020-05-18 Ironwood Pharmaceuticals, Inc. Stabilne formulacje linaklotydu
JP6312592B2 (ja) 2011-08-17 2018-04-18 アイアンウッド ファーマシューティカルズ インコーポレイテッド 消化器疾患の治療
EA022327B1 (ru) * 2013-01-04 2015-12-30 Общество С Ограниченной Ответственностью "Рубикон" Инъекционное ветеринарное средство в форме раствора для борьбы с полиинвазиями животного и способ его получения
CA2943906A1 (en) 2014-03-29 2015-10-08 Intas Pharmaceuticals Ltd. Liquid pharmaceutical composition of conjugated erythropoietin

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS6197229A (ja) * 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
AU593794B2 (en) * 1985-03-06 1990-02-22 Survival Technology Inc. Protein absorption enhancing agent

Also Published As

Publication number Publication date
PT88417A (pt) 1989-07-31
HK89495A (en) 1995-06-16
DK483188D0 (da) 1988-08-30
AU2173988A (en) 1989-04-27
HU202761B (en) 1991-04-29
NO178687B (no) 1996-02-05
PH25618A (en) 1991-08-08
NZ225975A (en) 1991-07-26
AU610636B2 (en) 1991-05-23
DK174811B1 (da) 2003-12-01
CS590188A2 (en) 1990-12-13
PL157944B1 (en) 1992-07-31
EP0306824A3 (en) 1990-01-31
LV10178B (en) 1995-04-20
DD273004A5 (de) 1989-11-01
ZA886528B (en) 1989-05-30
ES2051806T3 (es) 1994-07-01
GR3005454T3 (cs) 1993-05-24
IE882671L (en) 1989-03-05
FI884051L (fi) 1989-03-06
FI93517C (fi) 1995-04-25
CS274681B2 (en) 1991-09-15
JPS6471818A (en) 1989-03-16
EP0306824B1 (de) 1992-06-24
HUT47863A (en) 1989-04-28
NO883926L (no) 1989-03-06
CN1031801A (zh) 1989-03-22
US4992419A (en) 1991-02-12
DE3729863A1 (de) 1989-03-16
UA26123A (uk) 1999-06-07
UA26855C2 (uk) 1999-12-29
EP0306824A2 (de) 1989-03-15
KR890004718A (ko) 1989-05-09
JPH0780782B2 (ja) 1995-08-30
FI884051A0 (fi) 1988-09-02
LV10178A (lv) 1994-10-20
CN1027224C (zh) 1995-01-04
CA1330301C (en) 1994-06-21
PT88417B (pt) 1992-10-30
NO178687C (no) 1996-05-15
PL274485A1 (en) 1989-04-17
RU2043118C1 (ru) 1995-09-10
ATE77556T1 (de) 1992-07-15
DK483188A (da) 1989-03-06
FI93517B (fi) 1995-01-13
NO883926D0 (no) 1988-09-02
IE60310B1 (en) 1994-06-29
RU2100032C1 (ru) 1997-12-27
IL87628A0 (en) 1989-01-31
KR960009929B1 (ko) 1996-07-25
DE3872334D1 (de) 1992-07-30
MX12880A (es) 1993-12-01

Similar Documents

Publication Publication Date Title
IL87628A (en) Stabilised erythropoietin preparations and process for the production thereof
GR3018009T3 (en) Use of gamma-hydroxybutyric acid salts for preparing pharmaceutical compositions for use in the treatment of alcoholism, and the compositions obtained.
GR3025596T3 (en) Compositions and methods for identifying biologically active molecules.
IL96549A0 (en) Production of a biologically active protein
PL319833A1 (en) Compounds and composition for carrying active media
EP0279619A3 (en) Production of proteins in active forms
IL131381A0 (en) Therapeutic agent for lymphatic tumors
HUT43828A (en) Process for producing 1,1-disubstituted cyclopropan derivatives and pharmaceutical and/or fungicide compositions containing them as active agents
SG50379A1 (en) Improved peritoneal dialysis solutions with polypeptides
FR2607517B2 (fr) Vecteurs d'expression de variants de l'hirudine dans les levures, procede et produit obtenu
HUT43829A (en) Process for producing 1,1-disubstituted cyclopropan derivatives and pharmaceutical and/or fungicide compositions containing them as active agents
EP0315118A3 (en) Dna coding for endothelin and use thereof
AU2958789A (en) Amino acid amides with a psychotropic action, processes for their preparation, agents containing them and their use
DE3473826D1 (en) N,n-diethyl-5-methyl-2h-1-benzothiopyrano-(4,3,2-cd)-indazole-2-ethanamine, compositions comprising the same and uses therefor
EP0038153A3 (en) Modified allergens

Legal Events

Date Code Title Description
KB Patent renewed
RH Patent void
KB Patent renewed
KB Patent renewed
EXP Patent expired
EXP Patent expired